Lynch always suggests working with your health professional to review serum tests/lab work along with symptoms
When considering the use of Tirzepatide, patients must be aware of certain risks associated with the medication, including increased chances of pancreatitis, potential hypoglycemia, and thyroid tumors
Drink water before and after meals to support digestion, but avoid large fluid volumes during eating, which can cause discomfort on GLP-1 therapy
Ben LynchThyroid/Adrenal Webinar with Eve Scaba and Dr
Indeed, CDER Acting Director Michael Davis reinforced the policy point publicly on X, emphasizing that compounded GLP1 products are not FDAapproved and have not undergone the rigorous review for safety, efficacy, and manufacturing quality that is required for drugs approved through the new drug application (NDA) or abbreviated new drug application (ANDA) pathways.[3] This is now the third major set of warning letters in less than a year with the majority aimed at telehealth marketing of compounded GLP-1 products: September 2025: roughly 80 warning letters and 40 untitled letters March 2026: 30 warning letters June 2026: 25 warning letters The Claims FDA Is Targeting As in earlier rounds, the June 2026 letters appear highly standardized and focus on consumerfacing promotion of compounded GLP-1 products
PMID: 2839244
